Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Michel Aurrand-Lions is active.

Publication


Featured researches published by Michel Aurrand-Lions.


Nature Reviews Immunology | 2004

Adhesion mechanisms regulating the migration of monocytes

Beat A. Imhof; Michel Aurrand-Lions

Because of their phagocytic activity and their ability to differentiate into antigen-presenting cells, monocytes participate in both innate and adaptive immune responses. They derive from bone-marrow progenitor cells, circulate in the blood as monocytes and differentiate into tissue macrophages or myeloid dendritic cells in the periphery. After activation by an antigenic challenge in the tissues, they can contribute to the local resolution of the injury or can migrate farther to secondary lymphoid organs. Recruitment of these cells from the blood to the tissue and from the tissue to the lymph nodes requires orchestrated adhesive interactions between leukocytes and the vascular or lymphatic endothelium. Here, we discuss the signals by which chemokines regulate the leukocyte-adhesion molecules that are essential for transendothelial migration, and we describe the routes taken by monocytes and myeloid dendritic cells to reach their final destination.


Journal of Leukocyte Biology | 2006

Dual role of macrophages in tumor growth and angiogenesis

Chrystelle Lamagna; Michel Aurrand-Lions; Beat A. Imhof

During the neoplastic progression, macrophages as well as dendritic and NK cells are attracted into the tumor site and initiate the immune response against transformed cells. They activate and present tumor antigens to T cells, which are then activated to kill tumor cells. However, tumor cells are often capable of escaping the immune machinery. As the immune surveillance is not sufficient anymore, tumor‐associated macrophages contribute to tumor progression. It is notable that tumor‐associated macrophages promote the proliferation of tumor cells directly by secreting growth factors. They also participate in tumor progression by acting on endothelial cells and thus promoting the neovascularization of the tumor. Tumor‐associated macrophages are indeed key protagonists during angiogenesis and promote each step of the angiogenesis cascade.


Nature | 2004

Spermatid differentiation requires the assembly of a cell polarity complex downstream of junctional adhesion molecule-C

Georgia Gliki; Klaus Ebnet; Michel Aurrand-Lions; Beat A. Imhof; Ralf H. Adams

During spermatogenesis in the mammalian testis, stem cells (spermatogonia) differentiate into spermatocytes, which subsequently undergo two consecutive meiotic divisions to give rise to haploid spermatids. These cells are initially round but progressively elongate, condense their nuclei, acquire flagellar and acrosomal structures, and shed a significant amount of their cytoplasm to form spermatozoa (the sperm cells) in a developmental cascade termed spermiogenesis. Defects in these processes will lead to a lack of mature sperm cells (azoospermia), which is a major cause of male infertility in the human population. Here we report that a cell-surface protein of the immunoglobulin superfamily, junctional adhesion molecule-C (JAM-C), is critically required for the differentiation of round spermatids into spermatozoa in mice. We found that Jam-C is essential for the polarization of round spermatids, a function that we attribute to its role in the assembly of a cell polarity complex.


Journal of Cell Science | 2003

The junctional adhesion molecule (JAM) family members JAM-2 and JAM-3 associate with the cell polarity protein PAR-3: a possible role for JAMs in endothelial cell polarity.

Klaus Ebnet; Michel Aurrand-Lions; Annegret Kuhn; Friedemann Kiefer; Stefan Butz; Kerstin Zander; Maria-Katharina Meyer zu Brickwedde; Atsushi Suzuki; Beat A. Imhof; Dietmar Vestweber

Tight junctions play a central role in the establishment of cell polarity in vertebrate endothelial and epithelial cells. A ternary protein complex consisting of the cell polarity proteins PAR-3 and PAR-6 and the atypical protein kinase C localizes at tight junctions and is crucial for tight junction formation. We have recently shown that PAR-3 directly associates with the junctional adhesion molecule (JAM), which suggests that the ternary complex is targeted to tight junctions of epithelial cells through PAR-3 binding to JAM. The expression of JAM-related proteins by endothelial cells prompted us to test whether recruitment of the ternary complex in endothelial cells can occur through binding to JAM-2, JAM-3, endothelial cell-selective adhesion molecule (ESAM) or coxsackie- and adenovirus receptor (CAR). Here we show that the two JAM-related proteins JAM-2 and JAM-3 directly associate with PAR-3. The association between PAR-3 and JAM-2/-3 is mediated through the first PDZ domain of PAR-3. In agreement with the predominant expression of JAM-2 and JAM-3 in endothelial cells, we found that PAR-3 is expressed by endothelial cells in vivo and is localized at cell contacts of cultured endothelial cells. PAR-3 associates with JAM-2/-3 but not with the JAM-related Ig-superfamily members ESAM or CAR. In addition, we show that the tight junction-associated protein ZO-1 associates with JAM-2/-3 in a PDZ domain-dependent manner. Using ectopic expression of JAM-2 in CHO cells, we show that the junctional localization of JAM-2 is regulated by serine phosphorylation and that its clustering at cell-cell contacts recruits endogenous PAR-3 and ZO-1. Our findings suggest that JAM-2 affects endothelial cell junctions by its regulated clustering at intercellular contacts, and they support a role for JAM-2, and possibly JAM-3, in tight junction formation of endothelial cells.


Proceedings of the National Academy of Sciences of the United States of America | 2003

Crystal structure of human junctional adhesion molecule 1: Implications for reovirus binding

Andrea E. Prota; Jacquelyn A. Campbell; Pierre Schelling; J. C. Forrest; M. J. Watson; T. R. Peters; Michel Aurrand-Lions; Beat A. Imhof; Terence S. Dermody; Thilo Stehle

Reovirus attachment to cells is mediated by the binding of viral attachment protein σ1 to junctional adhesion molecule 1 (JAM1). The crystal structure of the extracellular region of human JAM1 (hJAM1) reveals two concatenated Ig-type domains with a pronounced bend at the domain interface. Two hJAM1 molecules form a dimer that is stabilized by extensive ionic and hydrophobic contacts between the N-terminal domains. This dimeric arrangement is similar to that observed previously in the murine homolog of JAM1, indicating physiologic relevance. However, differences in the dimeric structures of hJAM1 and murine JAM1 suggest that the interface is dynamic, perhaps as a result of its ionic nature. We demonstrate that hJAM1, but not the related proteins hJAM2 and hJAM3, serves as a reovirus receptor, which provides insight into sites in hJAM1 that likely interact with σ1. In addition, we present evidence that the previously reported structural homology between σ1 and the adenovirus attachment protein, fiber, also extends to their respective receptors, which form similar dimeric structures. Because both receptors are located at regions of cell–cell contact, this similarity suggests that reovirus and adenovirus use conserved mechanisms of entry and pathways of infection.


Nature Medicine | 2006

Angiogenesis and inflammation face off.

Beat A. Imhof; Michel Aurrand-Lions

Vascular endothelial cells respond to alarm signals of the body by angiogenesis or inflammation. The balance between these two responses is now pinned to two regulators of angiogenesis. Angiopoietin-1 dampens the inflammatory response, and angiopoietin-2 boosts it (pages 235–239).


Journal of Immunology | 2005

Junctional Adhesion Molecule-C Regulates the Early Influx of Leukocytes into Tissues during Inflammation

Michel Aurrand-Lions; Chrystelle Lamagna; John P. Dangerfield; Shijun Wang; Pedro Luis Herrera; Sussan Nourshargh; Beat A. Imhof

Leukocyte recruitment from blood to inflammatory sites occurs in a multistep process that involves discrete molecular interactions between circulating and endothelial cells. Junctional adhesion molecule (JAM)-C is expressed at different levels on endothelial cells of lymphoid organs and peripheral tissues and has been proposed to regulate neutrophil migration by its interaction with the leukocyte integrin Mac-1. In the present study, we show that the accumulation of leukocytes in alveoli during acute pulmonary inflammation in mice is partially blocked using neutralizing Abs against JAM-C. To confirm the function of JAM-C in regulating leukocyte migration in vivo, we then generated a strain of transgenic mice overexpressing JAM-C under the control of the endothelial specific promotor Tie2. The transgenic animals accumulate more leukocytes to inflammatory sites compared with littermate control mice. Intravital microscopy shows that this is the result of increased leukocyte adhesion and transmigration, whereas rolling of leukocytes is not significantly affected in transgenic mice compared with littermates. Thus, JAM-C participates in the later steps of the leukoendothelial adhesion cascade.


Cancer Research | 2005

Antibody against Junctional Adhesion Molecule-C Inhibits Angiogenesis and Tumor Growth

Chrystelle Lamagna; Kairbaan Hodivala-Dilke; Beat A. Imhof; Michel Aurrand-Lions

The junctional adhesion molecule-C (JAM-C) was recently described as an adhesion molecule localized at interendothelial contacts and involved in leukocyte transendothelial migration. The protein JAM-C interacts with polarity complex molecules and regulates the activity of the small GTPase Cdc42. The angiogenesis process involves rearrangement of endothelial junctions and implicates modulation of cell polarity. We tested whether JAM-C plays a role in angiogenesis using tumor grafts and hypoxia-induced retinal neovascularization. Treatment with a monoclonal antibody directed against JAM-C reduces tumor growth and infiltration of macrophages into tumors. The antibody decreases angiogenesis in the model of hypoxia-induced retinal neovascularization in vivo and vessel outgrowth from aortic rings in vitro. Importantly, the antibody does not induce pathologic side effects in vivo. These findings show for the first time a role for JAM-C in angiogenesis and define JAM-C as a valuable target for antitumor therapies.


Nature | 2010

Tumour angiogenesis is reduced in the Tc1 mouse model of Down’s syndrome

Louise E. Reynolds; Alan Watson; Marianne Baker; Tania A. Jones; Gabriela D'Amico; Stephen Robinson; Carine Joffre; Sarah Garrido-Urbani; Juan Carlos Rodríguez-Manzaneque; Estefanía Martino-Echarri; Michel Aurrand-Lions; Denise Sheer; Franca Dagna-Bricarelli; Dean Nizetic; Christopher J. McCabe; Andrew Turnell; Stéphanie Kermorgant; Beat A. Imhof; Ralf H. Adams; Elizabeth M. C. Fisher; Victor L. J. Tybulewicz; Ian R. Hart; Kairbaan Hodivala-Dilke

Down’s syndrome (DS) is a genetic disorder caused by full or partial trisomy of human chromosome 21 and presents with many clinical phenotypes including a reduced incidence of solid tumours. Recent work with the Ts65Dn model of DS, which has orthologues of about 50% of the genes on chromosome 21 (Hsa21), has indicated that three copies of the ETS2 (ref. 3) or DS candidate region 1 (DSCR1) genes (a previously known suppressor of angiogenesis) is sufficient to inhibit tumour growth. Here we use the Tc1 transchromosomic mouse model of DS to dissect the contribution of extra copies of genes on Hsa21 to tumour angiogenesis. This mouse expresses roughly 81% of Hsa21 genes but not the human DSCR1 region. We transplanted B16F0 and Lewis lung carcinoma tumour cells into Tc1 mice and showed that growth of these tumours was substantially reduced compared with wild-type littermate controls. Furthermore, tumour angiogenesis was significantly repressed in Tc1 mice. In particular, in vitro and in vivo angiogenic responses to vascular endothelial growth factor (VEGF) were inhibited. Examination of the genes on the segment of Hsa21 in Tc1 mice identified putative anti-angiogenic genes (ADAMTS1and ERG) and novel endothelial cell-specific genes, never previously shown to be involved in angiogenesis (JAM-B and PTTG1IP), that, when overexpressed, are responsible for inhibiting angiogenic responses to VEGF. Three copies of these genes within the stromal compartment reduced tumour angiogenesis, explaining the reduced tumour growth in DS. Furthermore, we expect that, in addition to the candidate genes that we show to be involved in the repression of angiogenesis, the Tc1 mouse model of DS will permit the identification of other endothelium-specific anti-angiogenic targets relevant to a broad spectrum of cancer patients.


Journal of Virology | 2005

Junctional Adhesion Molecule A Serves as a Receptor for Prototype and Field-Isolate Strains of Mammalian Reovirus

Jacquelyn A. Campbell; Pierre Schelling; J. Denise Wetzel; Elizabeth M. Johnson; J. Craig Forrest; Greame A. R. Wilson; Michel Aurrand-Lions; Beat A. Imhof; Thilo Stehle; Terence S. Dermody

ABSTRACT Reovirus infections are initiated by the binding of viral attachment protein σ1 to receptors on the surface of host cells. The σ1 protein is an elongated fiber comprised of an N-terminal tail that inserts into the virion and a C-terminal head that extends from the virion surface. The prototype reovirus strains type 1 Lang/53 (T1L/53) and type 3 Dearing/55 (T3D/55) use junctional adhesion molecule A (JAM-A) as a receptor. The C-terminal half of the T3D/55 σ1 protein interacts directly with JAM-A, but the determinants of receptor-binding specificity have not been identified. In this study, we investigated whether JAM-A also mediates the attachment of the prototype reovirus strain type 2 Jones/55 (T2J/55) and a panel of field-isolate strains representing each of the three serotypes. Antibodies specific for JAM-A were capable of inhibiting infections of HeLa cells by T1L/53, T2J/55, and T3D/55, demonstrating that strains of all three serotypes use JAM-A as a receptor. To corroborate these findings, we introduced JAM-A or the structurally related JAM family members JAM-B and JAM-C into Chinese hamster ovary cells, which are poorly permissive for reovirus infection. Both prototype and field-isolate reovirus strains were capable of infecting cells transfected with JAM-A but not those transfected with JAM-B or JAM-C. A sequence analysis of the σ1-encoding S1 gene segment of the strains chosen for study revealed little conservation in the deduced σ1 amino acid sequences among the three serotypes. This contrasts markedly with the observed sequence variability within each serotype, which is confined to a small number of amino acids. Mapping of these residues onto the crystal structure of σ1 identified regions of conservation and variability, suggesting a likely mode of JAM-A binding via a conserved surface at the base of the σ1 head domain.

Collaboration


Dive into the Michel Aurrand-Lions's collaboration.

Top Co-Authors

Avatar

Beat A. Imhof

Basel Institute for Immunology

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Sussan Nourshargh

Queen Mary University of London

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Jean-Paul Borg

Aix-Marseille University

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge